Century Therapeutics, Inc. (IPSC)
Century Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Philadelphia, PA, US. The stock last traded at $1.67, down 1.18% on the session, giving a market capitalisation of $144.6M. On trailing twelve-month figures it carries a trailing P/E of -1.61, a net margin of 0.0%. Its beta of 1.60 implies it has historically moved more than the broad market.
Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogeneic, induced pluripotent stem cell (iPSC)-derived CAR-iNK cell therapy. This therapy is specifically designed to target CD19 in patients with B-cell lymphoma that has relapsed or proven refractory to previous treatments. In addition to its lead candidate, the company's robust pipeline features several other therapeutic assets: CNTY-103: A CAR-iNK candidate aimed at CD133 + EGFR for recurrent glioblastoma. CNTY-102: A CAR-iT therapy targeting CD19 + CD79b, intended for relapsed or refractory B-cell lymphoma and other B-cell cancers. CNTY-104: A multi-specific CAR-iT or CAR-iNK candidate in development for acute myeloid leukemia. CNTY-106: Another multi-specific CAR-iNK or CAR-iT candidate for multiple myeloma. Established in 2018, Century Therapeutics, Inc. is based in Philadelphia, Pennsylvania.
Century Therapeutics, Inc. is most often compared with the following Healthcare names: